 we report on our second quarter 2020 financial results and discuss our plans for the second half of the year. 
 we also provide an update on our ongoing efforts to initiate the first phase 3 trial for cytisinicline, the non-inferiority RAUORA trial, which is the first direct head-to-head comparative study between cytisinicline and the current market leader, Chantix. 
 we also provide an update on the ongoing preparations for the upcoming phase 3 trial in the fourth quarter of this year, the ORCA-2 safety trial.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7#8 * # 1 *, # 2 ( # 4 ) # 3 ( # 4 ) # 5#6#7#8 *    # 1 *, # 2 ( # 3 ) # 1#2#3#4 # 5#6#7 * # 1 *, # 2 ( # 3